-
Sanofi launches Combiflam ICYHOT
expressbpd
September 12, 2017
The over-the-counter (OTC) product is available in two formats – gel and spray
-
Sanofi, Shire, Vertex and more back first-ever rare disease film festival
fiercepharma
August 31, 2017
Lucas DeFabio stars in one of the films set to be shown at the new rare-disease film festival, co-founded by his father, Daniel DeFabio, and Bo Bigelow.
-
Sanofi completes acquisition of Protein Sciences for $750m
pharmaceutical-technology
August 30, 2017
French pharmaceutical company Sanofi has completed the acquisition of US-based vaccine development firm Protein Sciences for $750m.
-
NICE looks to toss Sanofi and Ipsen thyroid cancer drugs from Cancer Drugs Fund
fiercepharma
August 24, 2017
NICE, which has been weeding out England's Cancer Drugs Fund, says it is not recommending that it pay for thyroid cancer drugs from Ipsen and Sanofi.
-
Sanofi shakes up agency team, adding WPP Group to media and creative partners
fiercepharma
August 22, 2017
To handle the creative side of its Sanofi business win, WPP plans to form an international Team Sanofi division.
-
Sanofi tip ends in $465M settlement between Mylan and DOJ
fiercepharma
August 18, 2017
Mylan announced it finalized a $465 million settlement relating to EpiPen's misclassification on Medicaid.
-
Sanofi files suit in the US to defend its patent rights on Lantus
cphi-online
August 11, 2017
Sanofi has filed a patent infringement suit to claims two patent rights on Lantus against Merck.
-
Sanofi files patent infringement suit against MSD in US
pharmatimes
August 10, 2017
Sanofi says that it has filed a patent infringement suit against Merck Sharp & Dohme in the United States District Court for the District of New Jersey, alleging the infringement of two patents.
-
Ablynx and Sanofi collaborate for nanobody-based inflammatory disease treatments
pharmaceutical-technology
July 24, 2017
Belgian biopharmaceutical company Ablynx has entered a research collaboration and global exclusive licensing agreement with French firm Sanofi to develop and commercialise nanobody-based therapeutics for the treatment of several immune-mediated inflammato
-
Sanofi, Ablynx sign $2.7bn research, licensing pact
pharmatimes
July 24, 2017
Sanofi has signed a research pact and licensing deal with Ablynx that could bring as much as $2.7 billion euros to the Belgian biotech’s coffers if all targets are met.
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight July 2025
